Multicenter observer-blind randomized phase II parallel study comparing three doses of subcutaneous interleukin 2 after megatherapy and peripheral stem cell reinfusion in stage 4 neuroblastoma in patients over 1 year of age.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Interleukin-2 (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions
- 17 Sep 2013 Biomarkers information updated
- 08 Feb 2009 Last checked against ClinicalTrials.gov record.
- 08 Feb 2009 Additional lead trial centre identified as reported by ClinicalTrials.gov.